GNLX insider trading
NasdaqCM HealthcareGENELUX Corp — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About GENELUX Corp
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Company website: www.genelux.com
GNLX insider activity at a glance
FilingIQ has scored 208 insider transactions for GNLX since Jan 26, 2023. The most recent filing in our index is dated May 11, 2026.
Across the full history, 10 open-market purchases
and 130 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on GNLX insider trades is 60.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest GNLX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for GNLX?
- FilingIQ tracks 208 Form 4 insider transactions for GNLX (GENELUX Corp), covering filings from Jan 26, 2023 onwards. 10 of those were filed in the last 90 days.
- Are GNLX insiders net buyers or net sellers?
- Across the full Form 4 history for GNLX, 10 transactions (5%) were open-market purchases and 130 (63%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does GNLX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is GNLX in?
- GENELUX Corp (GNLX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $117.84M.
Methodology & sources
Every GNLX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.